Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022

Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakth...

Descripción completa

Detalles Bibliográficos
Autores principales: Merad, Yanis, Gaymard, Alexandre, Cotte, Laurent, Perpoint, Thomas, Alfaiate, Dulce, Godinot, Matthieu, Becker, Agathe, Cannesson, Olivier, Batalla, Anne-Sophie, Oria-Yassir, Fatima, Landré, Sophie, Morfin, Florence, Bouscambert, Maude, Valour, Florent, Ader, Florence, Conrad, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808316/
https://www.ncbi.nlm.nih.gov/pubmed/36695469
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.50.2200882
Descripción
Sumario:Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases.

Ejemplares similares